About this Research Topic
Over the years, the insulin-like growth factor (IGF) signaling system has been widely recognized as holding pivotal roles in the occurrence and progression of various solid tumors. Small molecular compounds and antibodies targeting the IGF signaling pathway have also been developed for the treatment of a range of solid tumors. A similar emphasis has also been placed on the role of IGF in hematologic malignancies recently. Ample evidence highlighted the significance of the type I IGF receptor (IGF-IR) and its primary ligand, IGF-I, in sustaining the survival of malignant cells originating from the hematopoietic system.
In this Research Topic, we delve into the current understanding of the role of IGF signaling system in cancer, particularly emphasizing its impact on hematologic neoplasms. Furthermore, we aim to explore the potential of IGF-1/IGF-IR as a promising therapeutic target for treating various hematologic malignancies, encompassing plasma cell myeloma, leukemia, and lymphoma. We welcome authors to submit Original Research, Review, and Case Reports articles with a primary focus on, but not limited to, the following subtopics.
● The pathogenesis and molecular mechanisms of hematologic malignancies in terms of IGF signaling system
● Clinical studies and preclinical studies targeting the IGF signaling system
● Development of novel molecular targets for IGF signaling system in hematologic malignancies
● Novel chemical compounds targeting IGF signaling system for the treatment of hematologic malignancies
● IGF signaling system especially epigenetic mechanism in regulating clonal evolution, epigenetics in hematologic malignancies
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
In this Research Topic, we delve into the current understanding of the role of IGF signaling system in cancer, particularly emphasizing its impact on hematologic neoplasms. Furthermore, we aim to explore the potential of IGF-1/IGF-IR as a promising therapeutic target for treating various hematologic malignancies, encompassing plasma cell myeloma, leukemia, and lymphoma. We welcome authors to submit Original Research, Review, and Case Reports articles with a primary focus on, but not limited to, the following subtopics.
● The pathogenesis and molecular mechanisms of hematologic malignancies in terms of IGF signaling system
● Clinical studies and preclinical studies targeting the IGF signaling system
● Development of novel molecular targets for IGF signaling system in hematologic malignancies
● Novel chemical compounds targeting IGF signaling system for the treatment of hematologic malignancies
● IGF signaling system especially epigenetic mechanism in regulating clonal evolution, epigenetics in hematologic malignancies
Please note: Manuscripts consisting solely of bioinformatics, computational analysis, or predictions of public databases which are not accompanied by validation (independent clinical or patient cohort, or biological validation in vitro or in vivo, which are not based on public databases) are not suitable for publication in this journal.
Keywords: IGF1, IGF1R, leukemia, lymphoma, myeloma
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
